Navigation Links
Astellas Names Head of Global R&D Operations
Date:6/10/2009

DEERFIELD, Ill., June 10 /PRNewswire/ -- Astellas Pharma Global Development ("APGD"), a subsidiary of Astellas Pharma Inc. based in Tokyo, Japan, announced today that Dr. Peter Carberry, has been hired as the senior vice president and head of global development operations. Carberry is responsible for enhancing the effectiveness and efficiency of the integrated global operational platform including the data sciences and clinical operations organizations.

"We are pleased that Peter has joined Astellas and we know that he will contribute significantly to the development of innovative products," said Dr. Steven Ryder, president of APGD. "Peter is one of several key hires at APGD that were brought on to strengthen and accelerate our research and development function."

Prior to joining Astellas, Carberry was the vice president of clinical operations, development planning and performance analysis and the office of international development at Genentech. In that role, Carberry developed a global platform for the execution of non-clinical and clinical activities and established many key relationships with company stakeholders. Previously, Carberry was the senior vice president of global clinical operations at Johnson & Johnson Pharmaceutical Research and Development. Dr. Carberry began his industry career with Pharmacia at the Kalamazoo Research site where he held positions of increasing responsibility across the development organization. Carberry earned his M.D. at the University of Nairobi in Kenya and completed his Post Doctoral Fellowship in Clinical Pharmacology at the University of Texas. He earned his M.B.A. at Western Michigan University.

About Astellas

Astellas Pharma Global Development, located in Deerfield, Illinois, is a group company of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The organization is committed to becoming a global category leader in focused areas by combining outstanding R&D and marketing capabilities. For more information about Astellas Pharma Inc., please visit the website at http://www.astellas.com/en/.


'/>"/>
SOURCE Astellas Pharma Global Development
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Astellas Adds CNS Therapy Area Leader to Global R&D Team
2. Astellas Hires New Vice President of Compliance
3. Astellas Announces New Vice President of Marketing
4. Astellas Launches Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
5. Astellas/GlaxoSmithKlines Vesicare Has Advantages Over Pfizers Detrol LA/Detrusitol XL in Reducing Episodes of Urge Urinary Incontinence
6. FDA Approves Additional Indication for Astellas MYCAMINE(R)
7. Cardiome And Astellas Announce Regulatory Update
8. Spectrum Names Katherine Maynard Chief Operating Officer
9. Sarnova Names Hank Struik Chief Executive Officer
10. Aptium Oncology Names New Chief Operating Officer
11. National Parkinson Foundation Names New Chief Information Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... Intermedix ... of Emergency Medicine , an emergency medicine professional association, to support the organization's ... , The American Academy of Emergency Medicine, or AAEM, seeks to empower emergency ...
(Date:2/10/2016)... , ... February 10, 2016 , ... Emergency rooms provide ... to find. Unfortunately, this can leave patients with dental emergencies at risk of losing ... now offering emergency dental care. , Common dental emergencies include:, ...
(Date:2/10/2016)... ... February 10, 2016 , ... Dr. Jessica Barron, of ... is now accepting new dental patients and families in the North Metro Denver area. ... services from cleanings to cosmetic dentistry, and all in the most relaxing environment. , ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... organization, welcomes S.S. Nesbitt as the latest addition to its growing list of ... other locations throughout the Southeast, from Orlando to Huntsville and in between. , ...
(Date:2/10/2016)... ... , ... Armune BioScience signed a definitive agreement with ARCpoint ... across the country. Launched in April of 2015, Apifiny is the only cancer specific, ... order volume exceeded 3,000 tests in 2015. Primary care physicians and urologists have utilized ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... LONDON , February 10, 2016 A new report ... 2021 - states that the Alzheimer,s disease market will more than double ... 2021, at a Compound Annual Growth Rate (CAGR) of 11%. ... Italy , Spain , the UK, and ... prevalence during the forecast period. --> Canada , ...
(Date:2/10/2016)... SAN DIEGO , Feb. 10, 2016 ... viral gene therapy manufacturing, and Renova™ Therapeutics, a biopharmaceutical ... and other chronic diseases, have entered into a Manufacturing ... produce cGMP-grade RT-100 (Ad5.hAC6) Drug Product for use in ... --> This relationship will leverage Lonza,s ...
(Date:2/10/2016)... , Feb. 10, 2016 Immune Pharmaceuticals Inc. ... announced today that it has filed a patent application ... other cancers. --> --> ... by administration of Ceplene (histamine dihydrochloride) in combination with ... of predicting the efficacy of Ceplene and IL-2 therapy ...
Breaking Medicine Technology: